One of the case studies targeted reduction in IL-10 signaling, a major factor of T cell exhaustion in glioma microenvironment, by Janus kinase/signal transducer and activator of transcription (JAK-STAT) inhibitor, Ruxolitinib; however the patient showed stabilization for 8.5 months and was still alive up to the reporting of results [145]. This evidence concerns the gene IL10 and central nervous system cancer.